Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
|
Clinical Trials and Medical Research in Texas Create Jobs and Save Lives
Publish date: Mar 20, 2013
![]()
PR Newswire AUSTIN, Texas, March 20, 2013
AUSTIN, Texas, March 20, 2013 /PRNewswire/ --
WHO:
Sen. Bob Deuell (R) – Greenville; Rep. Jim Murphy
(R) – Houston; Tom Kowalski,
President, Texas Healthcare and Bioscience Institute;
Dr. Curtis Triplitt, Asst. Professor, Diabetes/Medicine, The University of Texas Health Science Center at San Antonio, Texas
Diabetes Institute; and Jeff Trewhitt, Senior Communications Director at PhRMA
WHAT:
A press conference on clinical trials of new medicines
being conducted in Texas by biopharmaceutical research companies in collaboration with local research institutions, including
The University of Texas and the release of a new report – "Research in Your Backyard: Pharmaceutical Clinical Trials
in Texas"
WHEN:
Monday, March 25
12:30-1:30 p.m.
WHERE:
Lt. Governor's Press Conference Room, Texas State Capitol,
Room 2E.9
WHY:
To emphasize the importance of biopharmaceutical research
companies to Texas patients and the state's economy, and the need for policies that support medical innovation; new clinical
trials are a steady source of revenue and business for local research institutions
SOURCE Texas Healthcare and Bioscience Institute
|
|